QPPV.COM KNOWLEDGE ASSESSMENT

Knowledge Assessment: Developing and Maintaining RMPs for Biological Medicinal Products

Test your understanding of the concepts covered by How to Develop and Maintain Risk Management Plans for Biological Medicinal Products.

Question 1 of 10Pass mark: 80%

Question 1 of 10 Which statement best describes the role of Module SVII?

It provides only a list of all adverse reactions reported worldwide. It provides the scientific evaluation of important identified and potential risks and missing information. It contains only the final public summary of the RMP. It is limited to the protocols for additional pharmacovigilance studies.

Question 2 of 10 Which scenario best represents an important potential risk?

A serious infection consistently associated with treatment in trials and post-authorisation data. A clinically relevant concern supported by coherent reports and biological plausibility, but with insufficient evidence to establish causality. A population that was not enrolled in trials but will never receive the product. A common mild injection-site reaction with no meaningful effect on benefit–risk.

Question 3 of 10 Which statement best distinguishes an EU RMP from a PBRER?

The RMP prospectively defines current uncertainties, additional evidence, controls and reassessment points, whereas the PBRER evaluates accumulated evidence over a defined period. The RMP is limited to adverse reactions already included in the product information, whereas the PBRER covers only unlabelled risks. The RMP evaluates manufacturing compliance, whereas the PBRER evaluates clinical efficacy only. The RMP is prepared only after authorisation, whereas the PBRER is required with the initial marketing-authorisation application.

Question 4 of 10 Which finding most strongly supports classification of a concern as an important identified risk?

A theoretical mechanism without human evidence. A single unverified report with no plausible temporal relationship. Adequate evidence of an association, together with potential impact on the benefit–risk balance or public health. An adverse reaction listed in the product information, regardless of seriousness or relevance.

Question 5 of 10 A new subcutaneous route may alter exposure and adherence compared with an established intravenous route. What is the most appropriate RMP response?

Assume the existing RMP applies without reassessment because the active substance is unchanged. Reassess the complete risk system, including local reactions, immunogenicity, medication errors, exposure and possible efficacy implications. Assess only manufacturing quality because the route does not affect clinical use. Replace all existing risks with a single route-related risk.

Question 6 of 10 Which statement correctly distinguishes Part IV from Part III?

Part IV concerns post-authorisation efficacy studies when efficacy uncertainty has benefit–risk implications; Part III concerns additional safety evidence. Part IV contains all routine pharmacovigilance activities; Part III contains only risk-minimisation measures. Part IV is limited to device complaints; Part III is limited to clinical trials. There is no substantive distinction between the two parts.

Question 7 of 10 Which pairing correctly distinguishes a process indicator from an outcome indicator for injector training?

Training-material distribution is an outcome indicator; correct preparation is a process indicator. Correct preparation is an outcome indicator; training-material distribution is a process indicator. Both are outcome indicators because both relate to training. Neither is useful because only spontaneous reports can assess effectiveness.

Question 8 of 10 What information should be defined for each additional pharmacovigilance activity?

Only the study title and anticipated publication date. The concern, objective, design, population, milestones and how results could change risk management. Only the number of investigators and participating countries. Only whether the activity is observational or interventional.

Question 9 of 10 Why is a reduction in reports of incomplete doses insufficient by itself to prove that injector training was effective?

Reports can fall because of under-reporting, reduced exposure or changes in reporting behaviour, as well as true improvement. Complaint reports are never relevant to risk-minimisation effectiveness. Training effectiveness can only be assessed through clinical trials. A reduction in reports proves that the risk has been eliminated.

Question 10 of 10 When does an under-represented population constitute missing information for an RMP?

Whenever the population was excluded from any clinical trial. Only when the population is larger than the studied population. When the gap is clinically relevant to authorised or expected use and limits safety prediction. Only when regulators have already identified an adverse reaction in that population.

Knowledge Assessment: Developing and Maintaining RMPs for Biological Medicinal Products

Cookie Settings